Nintedanib Eignapharma

Nintedanib, the active ingredient in Nintedanib Eignapharma, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution across EU and other regulated markets. The product meets European Union quality standards and is available for bulk and unit‑dose orders.

Nintedanib is used to target fibrotic lung diseases and certain cancers by inhibiting key growth factor receptors. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and angiogenesis.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Vomiting: occasional episodes. - Decreased appetite: reduced desire to eat. - Abdominal pain: discomfort in the stomach area. - Liver enzyme elevation: mild increase in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of transaminases or hepatitis. - Bleeding events: gastrointestinal or other hemorrhage. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Severe infections: opportunistic infections in immunocompromised patients.

Before initiating Nintedanib, several safety considerations should be reviewed. - Liver function: assess baseline hepatic enzymes and monitor regularly. - Bleeding risk: avoid in patients with active bleeding or uncontrolled hypertension. - Gastrointestinal health: monitor for severe diarrhea or dehydration. - Pregnancy and lactation: contraindicated or use only if benefits outweigh risks (category unknown). - Drug interactions: review concomitant medications that affect CYP3A4. - Store at ambient temperature: keep below 25 °C, in original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise levels. - P‑glycoprotein substrates (e.g., digoxin): possible altered concentrations. - Antihypertensives: monitor blood pressure as nintedanib may affect vascular tone. - Herbal supplements (e.g., St John’s wort): may reduce drug levels.